chrisvoncsefalvay/vaers-outcomes huggingface dataset:
It was reported that a pt received an Imovax Rabies ID vaccination administered on 10/12/01. On 10/22/01 the pt developed a generalized rash starting on her feet. She was seen by her family physician on 10/23/01, the rash is unresolved. Additional info received from mail correspondence at manufacturer on 4/22/02, it was reported that the rash was completely gone by 10/28/01. Allergist at hospital was seen and could not confirm but said it was most likely due to "serum sickness." Pt recovered.
Febrile seizure - 105.4 degrees. LOC completed - eyes roll back and shaking x 25-30 sec. at neck with family at incident.
Headache; muscle soreness; cramping/diarrhea; fatigue; sight injection pain; cramping; This is a spontaneous report from a contactable consumer (the patient). A 54-Year-old non-pregnant female patient received first dose bnt162b2 (Pfizer's COVID-19 vaccine, Solution for injection (Batch no: not reported, expiration: not reported), via an unspecified route of administration on Right arm on 27Feb2021 at 11:30 AM at single dose for covid-19 immunization. The patient medical history include neuropathy. The concomitant medications include Gabapentin, Eliquis, CBD/THC, Bariatric Vitamins. Patient was allergic to PCN, Demerol, Percocet, Iodine, latex, Tetanus. Patient did not have covid prior vaccination. Patient had not tested covid post vaccination. Patient did not had other vaccine in four weeks. On 27Feb2021 at 04:00 PM, the patient experienced headache, muscle soreness, cramping/diarrhea, fatigue and sight injection pain. The outcome of the events was recovering.  No follow-up attempts are possible. Information on the batch/lot number cannot be requested.
On 5/21/2021 at 1 pm, I developed itching on feet and hand about 24 hours after injection. 27 hours after injection of second dose (5/22/2021 at 4 pm), my lips began to swell. I took some Benadryl and swelling began to subside. Most of the swelling was gone within 24 hours of onset. Severe itching began 5/24/2021 at 6 am (65 hours after injection) around ankles. A rash spread up my legs, down arms, around the waist and splotches on the torso. I took more Benadryl and the rash decreased.  When Benadryl dose wears off, the rash comes back.
Post vax, after about 48 hours, member presents with larg (10cm x 9cm), itchy induration. No pain, no shortness of breath.
Pt complained of burning and tingling sensations throughout legs, arms, face.  Also complained of weakness upon standing.  Went to local physician the next day.  Labs were done which were all negative. Physician states it is a reaction to the H1N1 vaccine. No treatment. Pt referred to a neurologist.
Systemic: Allergic: Difficulty Breathing-Medium, Systemic: Blood Disorder  (diagnosed by MD)-Severe
Run fever for 12 days so far.  Had severe stomach cramps and diarrhea, aches and pain.  Severe pain in legs (felt like it was affecting my nerve endings somehow). My skin hurt to touch it.
Pain in joints of fingers; This is a spontaneous report from a contactable consumer, the parent. A 25-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 16Apr2021 at 10:00, (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included suspected COVID-19 in March 2020 but did not receive a COVID-19 test and therefore diagnosis was not clinically confirmed. The patient had no known allergies to medications, food or other products. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 16Mar2021 at 11:00 hours, (at the age of 25-year-old) as a single dose for COVID-19 immunisation. On 17Apr2021 at 01:00, the patient experienced pain in joints of fingers. No therapeutic measures were taken as a result of reported event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event pain in joints of fingers was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Started feeling sluggish 4 days after 2nd booster; Body aches started 4 days after 2nd booster; This spontaneous case was reported by a patient and describes the occurrence of SLUGGISHNESS (Started feeling sluggish 4 days after 2nd booster) and MYALGIA (Body aches started 4 days after 2nd booster) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     The patient's past medical history included COVID-19 (Exposed to COVID Virus more than 2 weeks prior to 2nd booster vaccine. Negative PCR more than 2 weeks prior to 2nd booster vaccine.).   On 24-Jun-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Jun-2022, the patient experienced SLUGGISHNESS (Started feeling sluggish 4 days after 2nd booster) and MYALGIA (Body aches started 4 days after 2nd booster). At the time of the report, SLUGGISHNESS (Started feeling sluggish 4 days after 2nd booster) and MYALGIA (Body aches started 4 days after 2nd booster) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Polymerase chain reaction: negative Negative.         No concomitant medication was reported. No treatment medication was reported.   This case was linked to MOD-2022-596502 (Patient Link).
felt warm-temp @ 4:30 103 temp @ 6:00 was 105.0 took to ER-vomitted x 24hr;
already had shingles when she got the vaccination; This case was reported by a consumer via interactive digital media (Shingrix GSK) and described the occurrence of off label use in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included shingles (already had a shingles at the time of vaccination.).   On 26th March 2021, the patient received Shingrix. On 26th March 2021, unknown after receiving Shingrix, the patient experienced off label use. On an unknown date, the outcome of the off label use was unknown.  Additional details were provided as follows: The case was reported by the husband of the patient. The age at vaccination was not reported. The patient received the Shingrix vaccine but the patient did not know at the time of vaccination that the symptoms she experienced within the last 2 weeks now made it appear that she already had shingles, which led to off label use. No further information reported.
Information has been received from a 29 year old male patient with a history of genital wart signs and abnormal genital cells while on previous therapy with a placebo (WAES1012USA02471) who was contacted at the end of B study in April 2010 for a "complementary" series of GARDASIL, as he was receiving the placebo. In April 2010, he was vaccinated with a dose of GARDASIL (Lot# unknown). A week later he started having genital itching, pain, bleeding, which had continued. It was reported that therapy was discontinued. It was unknown if the patient sought medical attention. Additional information has been requested.
Patient received a dose of the seasonal flu vaccine in our office on 10/08/18, dad called us on 10/12/18 to advise us that the patient had just received the flu vaccine again at her school. Dad stated that he had advised the school that she had already received the vaccine in our office on 10/08/18 and she wouldn't be participating in their flu clinic offered at the school, but on 10/12/18 dad found out that they had administered the flu vaccine again, dad then contacted and notified us. Patient is currently doing good per dad.
I95.9 HYPOTENSION 8/10/2022 ACUTE RESPIRATORY FAILURE J96.00 ACUTE RESPIRATORY FAILURE 8/28/2022 ACUTE RESPIRATORY FAILURE J96.90 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 8/29/2022 ACUTE RESPIRATORY FAILURE R57.9 SHOCK, UNSPECIFIED 8/28/2022 ACUTE RESPIRATORY FAILURE
Information has been received from a certified Medical Assistant concerning a female employee in her 30's, with carpal tunnel, who on 28, June 2006 was vaccinated intramuscularly in the left deltoid with a 1ml dose of hepatitis B virus vaccine rHBsAf (yeast) (Lot # 652348/1097R). Subsequently, within 20 minutes she developed tingling of her left hand, which resolved in 2-3 hours. Unspecified medical attention was sought. There was no product quality complaint involved. Additional information form the medical assistant indicated that the patient ; has had this numbness before because she has carpal tunnel.  the patient felt that this numbness was not a reaction to vaccination.
pt recvd vax; induration lt thigh at immun site; no fever; eating well; not irritable; tx w/ warm compress;
On 01/25/2023 in the late evening I went to the ER because I notice a painful node on back of my head. They thought it was in grown hair. They prescribe me with antibiotics and ibuprofen as per needed. I also noticed that I was having allergic reaction to the antibiotics and the ambulance had to come and get me to a different ER. At the new ER they prescribed me penicillin for 1 week. The bump on my head comes and goes. It is sensitive to touch. On 04/04/2023 I told my PCP and she prescribed me more penicillin but the bump is still there. I feel like once in a month it will come and go. As long as I take ibuprofen the pain is less.
Swelling of the upper lip. Pt was evaluated 10/23/2015 in the office, treated with prednisone, Zyrtec, Zantac, Benadryl. Swelling decreased over 10/24 & 10/25 & was gone by 10/26. No additional symptoms presented.
Area of ZOSTAVAX injection got red, swollen, hot, and painful beginning on Monday 9/19/11.
Pt vaccinated with meruvax II developed rash, generalized arthralgia & joint pain. Serological eval for arthritis negative; Treated w/Naproxen.
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. On or about 20-JAN-2015, the patient was inoculated with ZOSTAVAX (lot number, dosage and route of administration not provided), as recommended for routine adult health maintenance for the prevention of shingles. ZOSTAVAX did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. On or about 04-APR-2016, the patient was treated at a medical center for a blistering vesicular outbreak and decreased immune symptoms, which was then diagnosed as herpes zoster, or shingles. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events is unknown. Additional information has been requested.
Customer Safety Compromised: Nursing Mother-flu shot was given to a nursing mother, doctors note approved for participant to receive flu shot.
G45.9 TRANSIENT CEREBRAL ISCHEMIA 2/2/2023 TRANSIENT CEREBRAL ISCHEMIA G45.9 TRANSIENT CEREBRAL ISCHEMIA 2/2/2023 NONTRAUMATIC SUBARACHNOID HEMORRHAGE, UNSPECIFIED ARTERY
Arm swelling and Lymph nodes under the arm. Nausea, body aches and headache
I have never had heart issues and I am now in A-fib.  I believe this could have been brought on by the Johnson & Johnson Covid-19 Vaccination.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 34-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 10Aug2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 33 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovered" (19Aug2023) and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (19Aug2023) Negative; (20Aug2023) Negative. Therapeutic measures were taken as a result of drug ineffective, covid-19 which included received Paxlovid from 14Aug2023 to 18Aug2023.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Information has been received from a physician concerning a female (age not reported) who on an unspecified date was vaccinated with a second dose of Gardasil (lot# unknown) injection. On an unspecified date "sometime after the second dose of Gardasil the patient had a seizure. The physician reported that the patient went to the emergency room but did not know if she was admitted." There was no further adverse event information. On an unspecified date the patient recovered from the seizure. Upon internal review, seizure is considered to be an other medical event. Additional information has been requested.
This spontaneous report was received from a physician refers to a patient of 13 months old with unknown gender. No pertinent medical history was reported. On 18-SEP-2014, the patient was vaccinated with (Oka/Merck) VARIVAX (lot # K002920 and expiration date was 26-FEB-2016) dose 0.5 ml, subcutaneous injection. Concomitant medications was not reported. The physician reported that temperature excursions beginning 11-AUG-2014, with worst case exposure to -3.9C for 110 hours affecting (Oka/Merck) VARIVAX with lot # K002920 and expiration date 26-FEB-2016. Excursion supported for use within 3 months. No adverse effects reported. Patient did not sought medical attention. No Product Quality Complaint (PQC) was involved. This is one of the several reports from the same source. Additional information has been requested.
Information has been received from a physician concerning a 20 year old female who in approximately 2010 "about a year ago", was vaccinated with series doses of GARDASIL (lot number not reported). In 2011, "recently", the patient had tested positive high risk human papilloma virus (HPV). The patient sought medical attention by office visiting. At the time of this report, the patient's outcome was unknown. Additional information has been requested.
No other adverse event; temperature excursion; This spontaneous report has been received from a nurse referring to a patient of unknown age and gender. Information regarding the patient's medical history, drug reactions or allergies, concurrent conditions and concomitant medications was not provided.      On an unknown date, the patient was vaccinated with improperly stored dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) lot # 1637651 with expiration date of 09-JUN-2022, 0.5 milliliter (strength, indication, dose, route, frequency, anatomical location, lot # and expiration date were not provided) for prophylaxis. Other suspect therapies included and haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) lot number S021456 with expiration date of 25-FEB-2022 (strength, dose, route, frequency, and anatomical location were not provided) for prophylaxis. The vaccines were exposed to a temperature of 1.6 °C during a time frame of 8 hours.
Patient states that the day after receiving DAPTACEL vaccine, his arm was stiff. Gradually there become a lump in his axillae area, and today there is swelling to his chest area (same sided of injection).
pt recv vax 5JUN95 & 15JUN95 pt devel chickenpox; No further details were provided;
This spontaneous report as received from a 66 year old female patient with high blood pressure, high blood cholesterol and drug allergy to KEFLEX and codeine. The patient's medical history was not provided. On 18-NOV-2015, the patient was vaccinated with a dose of PNEUMOVAX 23 (lot #, expiration date and dose were not reported), intramuscular. Concomitant therapies included unspecified medications for high blood pressure and high blood cholesterol. On 18-NOV-2015, about 4 to 5 hours after receiving PNEUMOVAX 23, the patient experienced extreme pain in her arm. The pain was in the front of her arm, not at the injection site. On 19-NOV-2015 (reported as "the following day"), the patient had difficulty in moving her arm. There was no labs diagnostics studies performed. The patient contacted the pharmacy where she received PNEUMOVAX 23 and her arm was treated with ice. The patient also took an unspecified dose of ALEVE for pain relief. The patient also contacted her unspecified, primary physician and left a message, but has not heard back from him yet. The outcome of adverse events was reported as not recovered. The relatedness between adverse events and PNEUMOVAX 23 was not reported. Additional information has been requested.
This spontaneous report was received from a registered nurse (public health nurse) refers to multiple unspecified patients of unknown age and gender. The patient's pertinent medical history, allergic reactions and concomitant medications were unspecified. On unspecified dates, the patients were vaccinated with improperly stored doses of M-M-R II (lot # L043704, expiry date 04-NOV-2017, dose, strength, vaccination site, route unspecified). No adverse effect were reported. Product quality complaint (PQC) was not involved. No further information was provided. This is one of three reports received from the same reporter. Additional information has been requested.
Fever up to 102; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever up to 102) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Sep-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Sep-2021, the patient experienced PYREXIA (Fever up to 102). At the time of the report, PYREXIA (Fever up to 102) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 17-Sep-2021, Body temperature: 102 (High) Fever upto 102.         No concomitant medication reported. No treatment medication reported.  Reporter stated that patient was given booster dose and patient still had the event, fever even the next day morning.
2 days after my vaccination, randomly, the right part of my mouth went numb and the right part of my upper-lip swelled. I only get relations like this to things I eat. This happened while at work around 2:30pm and lasted until about 7pm
This spontaneous report as received from a nurse refers to a female patient of unknown age. On an unknown date, the patient was vaccinated with PNEUMOVAX 23 (lot#, exp. date, dose and route not provided). Then patient had not received a document of previous dose of PNEUMOVAX 23 but on an unknown date, within the last 5 years, the patient had been hospitalized for unspecified reasons and may have been vaccinated during previous hospitalization stays with PNEUMOVAX 23 (lot #, expiration date, dose and route not reported) during previous hospital stays. On an unknown date, directly after injection, the patient experienced injection site reactions which included swelling "to the size of grapefruits", redness and severe pain. The patient sought medical attention by office visit. The reactions were treated with unspecified steroids and antibiotics. At the time of the report, the outcome of the unspecified reasons why patient was hospitalized was unknown. The outcome of the events was reported as recovering. This is one of two reports received from the same source. Additional information has been requested.
Deltoid region indurated/deltoid region has been tender; Delayed injection site pain / quite painful to shoulder range of motion at the injection site / deltoid region has been tender; This spontaneous case was reported by a physician and describes the occurrence of VACCINATION SITE INDURATION (Deltoid region indurated/deltoid region has been tender) and VACCINATION SITE PAIN (Delayed injection site pain / quite painful to shoulder range of motion at the injection site / deltoid region has been tender) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE INDURATION (Deltoid region indurated/deltoid region has been tender) and VACCINATION SITE PAIN (Delayed injection site pain / quite painful to shoulder range of motion at the injection site / deltoid region has been tender). At the time of the report, VACCINATION SITE INDURATION (Deltoid region indurated/deltoid region has been tender) and VACCINATION SITE PAIN (Delayed injection site pain / quite painful to shoulder range of motion at the injection site / deltoid region has been tender) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported. No treatment medication was reported.
devel redness, swelling, warmth of rt deltoid area 6x3cm;
This spontaneous report as received from a medical assistant via a company representative refers to her daughter, an 11 year old female patient. The patient had no pertinent medical history and no drug allergies. On an unknown date the patient was vaccinated with the second dose of GARDASIL 9 (0.5 ml, intramuscular, lot # not provided). There were no concomitant medications. It was reported that (till the reporting time), the patient's arm had been "black and blue" around the injection site for seven days (onset date estimated to be 20-AUG-2015). The patient did not seek medical attention. No treatment was given. No lab diagnostics studies were performed. The medical assistant reported that her daughter would continue with the series of GARDASIL 9. The outcome was reported as recovering. Additional information has been requested.